Phase 2 COPD Trial, Recruiting NCT07606703 Sponsor: WeiShi Condition: COPD
Back to Copd

Phase 2 COPD Trial, Recruiting

NCT07606703
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand the study and are willing to sign a written consent form
  • People aged between 14 and 65 years
  • People who have been diagnosed with a specific form of chronic graft-versus-host disease (a condition that can occur after a stem cell or bone marrow transplant) that causes skin hardening, tightening of tissue beneath the skin, or limited joint movement, diagnosed using established 2014 guidelines
  • People who have previously been treated with steroid medicines for at least 12 months plus at least one other systemic (whole-body) treatment, OR who have received steroid medicines along with at least two other systemic treatments
  • People whose general physical functioning meets a minimum level as measured by a standard medical scoring tool (confirm with trial site)
  • People whose blood test results show a sufficient level of infection-fighting white blood cells (neutrophils above 1,000 per microlitre)
  • People whose blood test results show a sufficient level of platelets (at least 50,000 per microlitre)

Who may not be able to join:

  • People whose liver function blood test results show bilirubin levels more than 1.5 times the accepted upper normal limit
  • People whose kidneys are not filtering blood well enough, based on a standard kidney function measurement (confirm with trial site)
  • People who have an infection that is not currently under control
  • People who have heart or lung disease that is not currently under control
  • People with any other health condition that the trial doctor considers would make participation in the study unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 027-85726003

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
WeiShi
Registry
ClinicalTrials.gov
Start date
1 September 2025
Est. completion
1 March 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in Skin and/or Joint/Fascia NIH cGVHD Scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov